Experience is growing INVESTOR Q1 PRESENTATION 2018 INDIVA - PowerPoint PPT Presentation

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION TSXv: NDVA 1 / 28 our Experience is growing INVESTOR Q1 PRESENTATION

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 2 / 28 Forward The information contained herein, together with any amendments or supplements and any other information that may be furnished by the Looking company, includes forward-looking information. Such information is Statement based on assumptions as to future events that are inherently uncertain and subjective. The company makes no representation or warranty as to the attainability of such assumptions, including the completion of a fjnancing or as to whether future results will occur as projected. It must be recognized that the projections of the company’s future performance are necessarily subject to a high degree of uncertainty, that actual results can be expected to vary from the results projected and that such variances may be material and adverse. Prospective investors are expected to conduct their own investigation with regard to the company and its prospects. This presentation does not constitute an offer to sell or a solicitation of an offer to buy any security.

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 3 / 28 EXECUTIVE Executive Summary _____________________________________ 5 SUMMARY Timeline: Sales and Expansion ____________________________ 6 Table of Contents Growing Demand for Medical Cannabis ______________________ 8 INVESTING IN Recreational Cannabis Market _____________________________ 9 CANNABIS Insuffjcient Supply of Cannabis ____________________________ 10 Talented and Experienced Team ___________________________ 12 INDIVA Our High Quality Products ________________________________ 13 ADVANTAGES Our Unique Positioning ___________________________________ 14 Our Corporate Identity ___________________________________ 15 Customer Acquisition Strategies ____________________________ 16 Production Facility ______________________________________ 18 LONDON Production Facility Layout ________________________________ 19 FACILITY Production Facility Pictures _______________________________ 20 Domestic and International Growth: The Path to 40 Million Grams _ 23 PRODUCTION Operating Expenses _____________________________________ 25 Capex/Use of Funds _____________________________________ 26 AND FINANCIAL Comparables ___________________________________________ 27 PROJECTIONS

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION TSXv: NDVA 4 / 28 EXECUTIVE summary

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 5 / 28 NEAR TERM CATALYSTS: Executive Fully funded expansion to 40,000 square feet underway: Completion end of 2018 Summary Cultivation in progress: First 2 batches to be harvested Q1 2018 $ Sales license expected Q2 2018 STRONG INDUSTRY FUNDAMENTALS: 65%+ margin product, recurring revenue Experienced grower with award winning strains and loyal, installed Market demand growing exponentially 1,000+ patient base with introduction of $7 Billion recreational market by July 2018 Experienced management team, passionate about helping people Current supply and protecting investors

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 6 / 28 Timeline: Q2 2017: Construction complete (Phase 1) Sales and July 2017: Health Canada issues license to cultivate Expansion July 2017: Design for facility expansion begins September 2017: Cultivation begins Q1 2018: Expansion to 40,000 square feet begins Application Process Q2 2018: Harvests tested, full ACMPR license expected Preliminary Screening Q3 2018: Sales begin Enhanced Screening Security Clearance Q4 2018: Facility expansion complete Review Pre-License Inspection 2019: Full production capacity reached at London facility Cultivation License Cultivation Begins Sales License Annual Production: 2.5 to 3 million grams plus oils

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION TSXv: NDVA 7 / 28 INVESTING in cannabis

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 8 / 28 Growth rate of medicinal cannabis users is higher than expected Growing Health Canada projected 450,000 patients will be using cannabis at $1.3 billion annual value by 2024 At September 2017, there were 235,621 patients registered, which is a 17% quarter-over-quarter Demand increase and approximately equal to Health Canada’s projection for 2022 for Medical Health Canada’s Projected Registered Patients Actual Registered Patients 450,000 Cannabis 400,000 Registered Patients September 2017: registered 350,000 patients exceeds Health 300,000 Canada’s 2021 projection 250,000 10,433 physicians have 200,000 150,000 authorized patient access to 100,000 medicinal marijuana 50,000 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 235,621 registered patients in total to date Potential Market 11,000 (approx.) new 6,000,000 patients per month (~5% 5,000,000 month-over-month growth) 4,000,000 3,000,000 2,000,000 1,000,000 Multiple Risk of Migraine Life Stress Sclerosis Epilepsy Cancer Low BMI Severe Pain Depression Headaches Insomnia Anxiety Arthritis Hypertension (Elevated) Source: Health Canada, Statistics Canada, Canadian Community Health Survey, medicalmarijuana.ca

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 9 / 28 Size and Makeup of the Canadian Recreational Market Recreational According to the Deloitte Survey, the size Cannabis of the Canadian recreational cannabis market could be as much as $8.7 billion Market per year, or similar to the size of the Canadian spirit market. Annual Cannabis Users and Consumption Aged 15 and Over, Canada excluding Territories, Mid-point Estimates, 2018 Metric Tons Thousands 450 1,800 400 1,600 350 1,400 300 1,200 250 1,000 200 800 150 600 100 400 50 200 0 0 Once Less Than 1-3 Times per At Least Once a Daily Once a Month Month Week Consumption (LHS) Users (RHS) Source: Deloitte, PBO

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 10 / 28 Insuffjcient Current Production • 88 existing LPs Supply of • Current production < 84 insuffjcient to meet demand Cannabis Health Canada Market Data from Q3 2017 • Dry fmowers: 5.9 mm grams sold, 29.3mm grams in inventory • Oil: 7.7 mm grams sold, 8.6mm grams inventory • 235,621 registered clients at September 30, 2017 Number of licences • Prices range from $1.75/gram to $15/gram issued by province Deloitte Survey and PBO Report • Supplying even the low end of the estimate of the YT 0 recreational cannabis market would require the production NU NT 0 of over 700mm of cannabis annually 0 NL 0 BC 18 AB MB QC 4 2 6 PE SK 1 ON 4 48 NS 3 NB 2 Source: Health Canada; *Assumes 1 gram/day/patient

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION TSXv: NDVA 11 / 28 INDIVA advantages

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 12 / 28 FINANCE & CORPORATE DEVELOPMENT REGULATORY & QA Niel Marotta President & CEO, Director, Founder John McCluskey Vice President of Regulatory Affairs & Quality Assurance • Managed over $1 Billion across several Talented and industries • 15+ years of Quality Assurance experience • Involved in capital raises and M&A • Acted as a consultant on over 30 ACMPR Experienced transactions exceeding $1 Billion applications Team LEGAL & BUSINESS DEVELOPMENT PRODUCTION AND PATIENT CARE Koby Smutylo COO, General Counsel, Pete Young Master Grower Director, Founder • Grow Team: 15+ years of experience producing • Koby is a seasoned lawyer and has acted as medicinal strains for hundreds counsel to private and public companies of patients • International recognition and multiple • Helped fjnance and license an ACMPR LP product awards FINANCE QUALITY ASSURANCE & SCIENCE Jennifer Welsh Chief Financial Offjcer Daniel Zavitz PHD • Managed a global fjnance team for eight years • Over 30 years experience in research, lab as Corporate Controller of a TSX listed compliance and QA company • Former consultant for a publicly traded LP SECURITY David Hyde Security Consultant CREATIVE • Leading expert in ACMPR security compliance Tom Borowicz Marketing & Branding PROJECT DEVELOPMENT • Over 30 years of combined experience in marketing, branding, print/digital advertising Jose Laurentino Project Management and design with Fortune 500 companies • 20+ years in agricultural project development including indoor and greenhouse expertise

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 13 / 28 INDIVA’s strains were developed over several decades of working compassionately with individuals in need. Our grow team is led by Our a “master grower” that is recognized in Canada and internationally High Quality as a leader in the fjeld of cannabis cultivation. Products High-quality medical and recreational cannabis products Edibles Available When Legal

2018 INDIVA TSXv: NDVA INVESTOR PRESENTATION 14 / 28 INDIVA Is Inclusive INDIVA will capture the market at the Our Unique intersection of medical and recreational MEDICINAL RECREATIONAL cannabis markets. Positioning CANNABIS CANNABIS INDIVA Is Experience Our master grower has mastered cannabis cultivation over decades of experience MMAR ACMPR and experimentation with different growing REGULATORY REGULATORY techniques. His expertise is held up to strict SYSTEM SYSTEM standards enforced by John McCluskey, a Quality Assurance expert with 20+ years of experience in the pharmaceutical industry. The INDIVA facility is a manifestation of both industries.